Construction and Validation of TACE Therapeutic Efficacy by ALR Score and Nomogram: A Large, Multicenter Study
暂无分享,去创建一个
Kun He | Han Li | Yunwei Han | Lu Guo | Ke Su | Zhenying Wu | Jiali Chen | Yi Jiang | Hao-min Zeng | Pan Wang | T. Gu | Lei Han | Hao Chi | Lu Guo | Ke Xu | Jiali Chen | Pan Wang | Ke Xu | Zhenying Wu | Changlun Li | Han Li | Yunwei Han | Wenxi Zhao | Hao Zeng | Lei Han | Yi Jiang | Ke Su | Changlun Li | Tao Gu | Kun He | Hao Chi | Wenxi Zhao
[1] J. Li,et al. A novel nomogram to predict survival of patients with hepatocellular carcinoma after transarterial chemoembolization: a tool for retreatment decision making , 2023, Annals of Translational Medicine.
[2] Zuo-jin Liu,et al. PNI-Based Nomograms to Predict Tumor Progression and Survival for Patients with Unresectable Hepatocellular Carcinoma Undergoing Transcatheter Arterial Chemoembolization , 2023, Journal of clinical medicine.
[3] T. Therneau,et al. Prognostic utility of systemic inflammatory markers and chronic hepatitis C virus infection status in hepatocellular carcinoma patients treated with local ablation , 2022, BMC cancer.
[4] Min Zhang,et al. Prognostic and Clinical Significance of Aspartate Aminotransferase-to-Lymphocyte Ratio Index in Individuals with Liver Cancer: A Meta-Analysis , 2022, Disease markers.
[5] Jia Liu,et al. Epigenetic and Immune-Cell Infiltration Changes in the Tumor Microenvironment in Hepatocellular Carcinoma , 2021, Frontiers in Immunology.
[6] Shanshan Wang,et al. Progression on the Roles and Mechanisms of Tumor-Infiltrating T Lymphocytes in Patients With Hepatocellular Carcinoma , 2021, Frontiers in Immunology.
[7] A. Morishita,et al. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review , 2021, International journal of molecular sciences.
[8] R. Miksch,et al. The predictive value of tumor infiltrating leukocytes in Hepatocellular Carcinoma: A systematic review and meta-analysis. , 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[9] S. Raman,et al. Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.
[10] Hong Wu,et al. The density of tumor-infiltrating lymphocytes and prognosis in resectable hepatocellular carcinoma: a two-phase study , 2021, Aging.
[11] R. Lencioni,et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma , 2021, Nature Reviews Gastroenterology & Hepatology.
[12] Y. Chang,et al. Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma , 2020, International journal of molecular sciences.
[13] Y. Lv,et al. The prognostic significance of serum gamma-glutamyltransferase levels and AST/ALT in primary hepatic carcinoma , 2019, BMC Cancer.
[14] T. de Baère,et al. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. , 2019, Cancer treatment reviews.
[15] B. Carr,et al. Analysis of aggressiveness factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization , 2018, World journal of gastroenterology.
[16] T. Tang,et al. Aspartate aminotransferase-to-platelet ratio predicts response to transarterial chemoembolisation and prognosis in hepatocellular carcinoma patients. , 2017, Clinical radiology.
[17] P. Galle,et al. Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma. , 2016, Journal of vascular and interventional radiology : JVIR.
[18] M. Garnelo,et al. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma , 2015, Gut.
[19] L. Bolondi,et al. The ART Score Is Not Effective to Select Patients for Transarterial Chemoembolization Retreatment in an Italian Series , 2014, Digestive Diseases.
[20] J. Cercueil,et al. Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma. , 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[21] H. Heinzl,et al. The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma , 2013, Hepatology.
[22] L. Roberts,et al. Epidemiology and management of hepatocellular carcinoma. , 2010, Infectious disease clinics of North America.
[23] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.